If one is on short-term ADT, does the duration of concurrent anti-androgen matter?

Key sentence from the paper: “… for men with no or minimal comorbidity, it appears that the delivery of full versus dose-reduced [anti-androgens] was not associated with prolonged survival…suggesting that supplementing the LHRH agonist therapy with and [anti-androgen] for ~4 rather than 6 months may be sufficient to minimize death from [prostate cancer] and prolong survival as compared with no ADT use.

Read More